Caribou Biosciences to Participate in Upcoming Investor Conferences
01. Mai 2024 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24. April 2024 10:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15. April 2024 09:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
04. April 2024 16:00 ET
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11. März 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
05. März 2024 16:30 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
Caribou Biosciences to Participate in Upcoming Investor Conferences
15. Februar 2024 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
07. Januar 2024 11:00 ET
|
Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12. Dezember 2023 16:02 ET
|
Caribou Biosciences, Inc.
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
07. November 2023 16:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- ...